Developing Genomic Biomarkers for Early Safety Screens for Non-genotoxic Carcinogenicity
*Nandini Raghavan, Johnson & Johnson Pharmaceutical Research & Development Keywords: Prediction Rule, Biomarker, Toxicogenomics, Non-genotoxic Carcinogenicity, Gene Signature, Classification There is now an increasing recognition of the need to develop robust preclinical safety biomarkers, as elucidated in various reports (FDA (2006), NRC(2007)). A primary focus is to develop prediction rules for different types of toxicities, especially non-genotoxic carcinogenicity, since this occurs in a significant proportion of compounds tested in rodents, and for which short-term assays have been difficult to develop. In this talk, we describe a novel approach for developing genomic prediction rules for non-genotoxic carcinogenicity based on 24-hr microarray studies on rats. Our methodology offers a robust and clearly generalizable approach for developing such rules in a variety of other settings. We also briefly describe an independent effort currently underway at the PSTC to develop and validate a custom genomic assay based on genes culled from published literature.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC